Gilead Sciences Inc (GILD)
Gilead Sciences Inc (GILD) carries a ŷRobot AI score of 64 out of 100. The model's fair value estimate is $178.70, 6.3% above the last close of $168.08. The chart signal reads Bearish.
| Metric | GILD |
|---|---|
| AI score | 64 / 100 |
| Chart signal | Bearish |
| Fair value estimate | $178.70 |
| Upside to fair value | 6.3% |
| Previous close | $168.08 |
| P/E | -54.42 |
| Price / sales | 6.82 |
| Market cap | $210.52B |
| EPS | -3.13 |
| Revenue growth | 2.9% |
| 1-year price change | 6.2% |
How these numbers are built: the AI score, the fair value model, and the chart signal.
Other Healthcare stocks: Eli Lilly and Company, Johnson & Johnson, AbbVie Inc, Merck & Company Inc, UnitedHealth Group Incorporated, Novartis AG ADR.
Questions about GILD
Is GILD overvalued or undervalued right now?
As of Nov 2, 2026, ŷRobot's fair-value model estimates Gilead Sciences Inc (GILD) at $178.70 against a last close of $168.08, implying 6.3% upside to the model's estimate.
Is GILD's chart signal bullish or bearish?
The chart-signal model classifies GILD as Neutral as of Nov 13, 2026, with a signal score of -0.09 on a -1 to 1 scale.
What is GILD's ŷRobot AI score?
GILD scores 64 out of 100 on ŷRobot's AI composite, which measures how strongly the fair-value and chart models agree, as of Nov 13, 2026.
Is GILD stock expensive on P/E and P/S?
GILD trades at -54.4 times earnings and 6.8 times sales as of Nov 13, 2026.
What does GILD's seasonal forecast show?
ŷRobot's seasonal forecast curve for GILD reads +0.3% at 30 days, +2.9% at 90 days, and +6.2% at one year as of Nov 13, 2026. Seasonal tendencies are historical patterns, not predictions.
How fast is GILD growing?
Gilead Sciences Inc's revenue growth is +2.9% and free-cash-flow growth is +865.8% on the latest reported figures.
GILD chart and technical read · All covered stocks
ŷRobot analysis is AI-generated and quality-gated; nothing here is investment advice.